Shuimu BioSciences
Cambridge
About Shuimu BioSciences
Shuimu harnesses the power of cryo-EM and Artificial Intelligence to help pharma and biotech companies discover and develop novel therapeutics faster and better, breaks new ground to develop precision medicines for the most challenging diseases on our planet. With eight 300kv Cryo-EM’s in house, proprietory GraFuture technologies, AI driven data processing and modeling platforms, Shuimu is your best partner with one-stop solutions in structure based drug and therapeutic innovation, from sequence to structure.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2022)
- Website: shuimubio.com
- Phone: 650-680-9298
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/shuimu-biosciences-146296 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.